Immunotherapy drug gives non-small-cell lung cancer patients extra four months of life with fewer side effects compared to chemotherapy
Tuesday, December 13, 2016 - 14:31
in Health & Medicine
Patients with advanced non-small-cell lung cancer survive four months longer with fewer side effects on an immunotherapy drug called atezolizumab compared to chemotherapy, according to a phase 3 clinical trial.